Zentalis Pharma Q2 EPS $(1.85) Misses $(1.04) Estimate. Cash and Equivalents of $553M
Portfolio Pulse from Benzinga Newsdesk
Zentalis Pharma reported Q2 losses of $1.85 per share, missing the analyst consensus estimate of $1.04 by 77.88%. This represents a 38.06% increase in losses compared to the same period last year. The company also reported cash and equivalents of $553M.
August 09, 2023 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Zentalis Pharma's Q2 earnings were significantly below analyst expectations, with losses increasing by 38.06% compared to the same period last year.
Zentalis Pharma's earnings miss and increased losses YoY are likely to negatively impact investor sentiment and could lead to a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100